ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Ying Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4440-5803; OpenAlex author ID A5092484301. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation. Co-author DOI 10.1016/j.bcp.2026.118222 ↗
Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity and therapeutic efficacy against pancreat… Co-author DOI 10.1016/j.ejps.2025.107188 ↗
Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. Co-author DOI 10.1016/j.bmcl.2020.127725 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yong‐Su Zhen · 2 shared papers, 2025–2026 · strength 0.57
- Paper hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and… DOI 10.1016/j.bcp.2026.118222 ↗
- Paper Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity a… DOI 10.1016/j.ejps.2025.107188 ↗
D X Zhou · 1 shared paper, 2026 · strength 0.29
- Paper hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and… DOI 10.1016/j.bcp.2026.118222 ↗
Qingfang Miao · 1 shared paper, 2026 · strength 0.29
- Paper hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and… DOI 10.1016/j.bcp.2026.118222 ↗
Weijin Sheng · 1 shared paper, 2025 · strength 0.28
- Paper Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity a… DOI 10.1016/j.ejps.2025.107188 ↗
Xingpeng Shi · 1 shared paper, 2021 · strength 0.17
- Paper Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase … DOI 10.1016/j.bmcl.2020.127725 ↗
Yanping Li · 1 shared paper, 2021 · strength 0.17
- Paper Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase … DOI 10.1016/j.bmcl.2020.127725 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.